Peptide mimotopes of carbohydrate antigens

Immunologic Research

Volumn 17, Issue 1-2, 1998, Pages 95-108

  Kieber Emmons, Thomas ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Adjuvants; Carbohydrate antigens; Lewis Y; Peptide mimotopes; Vaccine

Indexed keywords

CARBOHYDRATE ANTIGEN;

ARTICLE; IMMUNE RESPONSE; PRIORITY JOURNAL; VACCINATION;

EID: 0031938173     PISSN: 0257277X     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF02786435     Document Type: Article

References (66)

1. Hakomori S: Aberrant glycosylation in tumors and tumor-associated carbohydrate antigens. Adv Cancer Res 1989;52:257-331.
2. Hakomori S: Possible functions of tumor-associated carbohydrate antigens. Curr Opinion Immunol 1991;3:646-653.
3. Mond JJ, Lees A, Snapper CM: T cell-independent antigens type 2 [Review]. Annu Rev Immunol 1995;13(655):655-692.
4. Zhang S, Walberg LA, Ogata S, Itzkowitz SH, Koganty RR, Reddish M, Gandhi SS, Longenecker BM, Lloyd KO, Livingston PO: Immune sera and monoclonal antibodies define two configurations for the sialyl Tn tumor antigen. Cancer Res 1995;55(15):3364-3368.
5. Livingston PO: Approaches to augmenting the immunogenicity of melanoma gangliosides: from whole melanoma cells to ganglioside-KLH conjugate vaccines. [Review]. Immunol Rev 1995; 145(147):147-166.
6. Westerink MA, Apicella MA: Anti-idiotypic antibodies as vaccines against carbohydrate antigens [Review]. Springer Semin Immunopathol 1993;15(2-3):227-234.
7. Berzofsky JA: Antigenic peptide interaction with MHC molecules: implications for the design of artificial vaccines [Review]. Semin Immunol 1991;3(4):203-16.
8. Westerink MAJ, Giardina PC, Apicella MA, Kieber-Emmons T: Peptide mimicry of the meningococcal group C capsular polysaccharide. Proc Natl Acad Sci USA 1995;92:4021-4025.
9. Kieber-Emmons T, Luo P, Agadjanyan M, Hutchins W, Westreink M, Steplewski Z: Peptide mimicry of tumor associated carbohydrate antigens. Hybridoma 1996;16:3-10.
10. Agadjanyan M, Lou P, Westerink MAJ, Carey LA, Hutchins W, Steplewski Z, et al.: Peptide mimicry of carbohydrate epitopes on human immunodeficiency virus. Nat Biotechnol 1997;15:547-551.
11. Saleh MN, Stapleton JD, Khazaeli MB, LoBuglio AF: Generation of a human anti-idiotypic antibody that mimics the GD2 antigen. J Immunol 1993;151(6):3390-3398.
12. Hoess R, Brinkmann U, Handel T, Pastan I: Identification of a peptide which binds to the carbohydrate-specific monoclonal antibody B3. Gene 1993;128(1):43-49.
13. Scott JK, Loganathan D, Easley RB, Gong X, Goldstein IJ: A family of concanavalin A-binding peptides from a hexapeptide epitope library. Proc Natl Acad Sci USA 1992;89(12): 5398-5402.
14. Oldenburg KR, Loganathan D, Goldstein IJ, Schultz PG, Gallop MA: Peptide ligands for a sugar-binding protein isolated from a random peptide library. Proc Natl Acad Sci USA 1992;89(12):5393-5397.
15. Thurin-Blaszczyk M, Murali R, Westerink MAJ, Steplewski Z, Co M-S, Kieber-Emmons T: Molecular recognition of the Lewis Y antigen by monoclonal antibodies. Protein Engin 1996;9:101-113.
16. Yamada N, Chung YS, Maeda K, Sawada T, Ikehara T, Nishino H, Okuno M, Sowa M: Increased expression of sialyl Lewis A and sialyl Lewis X in liver metastases of human colorectal carcinoma. Invasion & Metastasis 1995;15(3-4):95-102.
17. Ikeda Y, Mori M, Kajiyama K, Haraguchi Y, Sasaki O, Sugimachi K: Immunohistochemical expression of sialyl Tn, sialyl Lewis a, sialyl Lewis a-b-, and sialyl Lewis x in primary tumor and metastatic lymph nodes in human gastric cancer. J Sur Oncol 1996;62(3):171-176.
18. Dennis JW, Laferte S: Oncodevelopmental expression of GlcNAcb1,6 Mana1,6 Mana1-branched asparagine-linked oligosaccharides in murine tissues and human breast carcinoma. Cancer Res 1989;49: 945-950.
19. Hiraizumi S, Takasaki S, Ochuchi N, Harada Y, Nose M, Mori S, et al.: Altered glycosylation of membrane glycoproteins associated with human mammary carcinoma. Jpn J Cancer Res 1992;83:1063-1072.
20. MacLean GD, Reddish M, Koganty RR, Wong T, Gandhi S, Smolenski M, et al.: Immunization of breast cancer patients using a synthetic sialyl-Tn glycoconjugate plus Detox adjuvant. Cancer Immunol Immunother 1993;36(4):215-222.
21. Springer GF, Desai PR, Tegtmeyer H, Carlstedt SC, Scanlon EF: T/Tn antigen vaccine is effective and safe in preventing recurrence of advanced human breast carcinoma. Cancer Biother 1994;9(1):7-15.
22. Toyokuni T, Hakomori S, Singhal AK: Synthetic carbohydrate vaccines: synthesis and immunogenicity of Tn antigen conjugates. Bioorganic Med Chem 1994;2(11):1119-1132.
23. Bremer EG, Levery SB, Sonnino S, Ghidoni R, Canevari S, Kannagi R, et al.: Characterization of a gly-cosphingolipid antigen defined by the monoclonal antibody MBR1 expressed in normal and neoplastic epithelial cells of human mammary gland. J Biol Chem 1984;259: 14,773-14,777.
24. Nakagoe T, Fukushima K, Hirota M, Kusano H, Kawahara K, Ayabe H, et al.: Immunohistochemical expression of blood group substances and related carbohydrate antigens in breast carcinoma. Jpn J Cancer Res 1991;82:559-568.
25. Hoff SD, Matsushita Y, Ota DM, Cleary KR, Yamori T, Hakomori S, et al.: Increased expression of sialyl-dimeric LeX antigen in liver metastases of human colorectal carcinoma. Cancer Res 1989;49 (24Pt1):6883-6888.
26. Hoff SD, Irimura T, Matsushita Y, Ota DM, Cleary KR, Hakomori S: Metastatic potential of colon carcinoma. Expression of ABO/ Lewis-related antigens. Arch Surg 1990;125(2):206-209.
27. Blaszczyk-Thurin M, Thurin J, Hindsgaul O, Karlsson KA, Steplewski Z, Koprowski H: Y and blood group B type 2 glycolipid antigens accumulate in a human gastric carcinoma cell line as detected by monoclonal antibody. Isolation and characterization by mass spectrometry and NMR spectroscopy. J Biol Chem 1987;262(1):372-379.
28. Rodeck U, Herlyn M, Leander K, Borlinghaus P, Koprowski H: A mucin containing the X, Y, and H type 2 carbohydrate determinants is shed by carcinoma cells. Hybridoma 1987;6:389-401.
29. Miyake M, Taki T, Hitomi S, Hakomori S: The correlation of expression of H/Ley/Leb antigens with survival of patients with carcinoma of the lung. Biochemistry 1992;327:14-18.
30. Shimizu T, Yonezawa S, Tanaka S, Sato E: Expression of Lewis X-related antigens in adenocarcinomas of lung. Histopathology 1993;22(6):549-555.
31. Sun J, Thurin J, Cooper HS, Wang P, Mackiewicz M, Steplewski Z, et al.: Elevated expression of H type GDP-L-fucose:beta-D-galactoside alpha-2-L-fucosyltransferase is associated with human colon adenocarcinoma progression. Proc Natl Acad Sci USA 1995;92(12):5724-5728.
32. Yazawa S, Nakamura J, Asao T, Nagamachi Y, Sagi M, Matta KL, et al.: Aberrant alpha 1→2 fucosyltransferases found in human colorectal carcinoma involved in the accumulation of Leb and Y antigens in colorectal tumors. Jpn J Cancer Res 1993;84(9):989-995.
33. Livingston PO: Construction of cancer vaccines with carbohydrate and protein (peptide) tumor antigens [Review]. Curr Opinion Immunol 1992;4(5):624-629.
34. Livingston PO, Calves MJ, Helling F, Zollinger WD, Blake MS, Lowell GH: GD3/proteosome vaccines induce consistent IgM antibodies against the ganglioside GD3. Vaccine 1993;11(12):1199-1204.
35. Livingston PO, Adluri S, Helling F, Yao TJ, Kensil CR, Newman MJ, Marciani D: Phase 1 trial of immunological adjuvant QS-21 with a GM2 ganglioside-keyhole limpet haemoeyanin conjugate vaccine in patients with malignant melanoma. Vaccine 1994;12(14): 1275-1280.
36. Longenecker BM, Reddish M, Koganty R, MacLean GD: Immune responses of mice and human breast cancer patients following immunization with synthetic sialyl-Tn conjugated to KLH plus detox adjuvant. Ann NY Acad Sci 1993;690(276):276-291.
37. Longenecker BM, Reddish M, Koganty R, MacLean GD: Specificity of the IgG response in mice and human breast cancer patients following immunization against synthetic sialyl-Tn, an epitope with possible functional significance in metastasis. Adv Exp Med Biol 1994;353(105):105-124.
38. Ravindranath MH, Morton DL: Role of gangliosides in active immunotherapy with melanoma vaccine [Review]. Int Rev Immunol 1991;7(4):303-329.
39. Helling F, Shang A, Calves M, Zhang S, Ren S, Yu RK, et al.: GD3 vaccines for melanoma: superior immunogenicity of keyhole limpet hemocyanin conjugate vaccines. Cancer Res 1994;54(1): 197-203.
40. Helling F, Zhang S, Shang A, Adluri S, Calves M, Koganty R, et al.: GM2-KLH conjugate vaccine: increased immunogenicity in melanoma patients after administration with immunological adjuvant QS-21. Cancer Res 1995;55 (13):2783-2788.
41. Kitamura K, Livingston PO, Fortunato SR, Stocked E, Helling F, Ritter G, et al.: Serological response patterns of melanoma patients immunized with a GM2 ganglioside conjugate vaccine. Proc Natl Acad Sci USA 1995; 92(7):2805-2809.
42. Adluri S, Helling F, Ogata S, Zhang S, Itzkowski SH, Lloyd KO, et al.: Immunogenicity of synthetic TF-KLH (keyhole limpet hemocyanin) and sTn-KLH conjugates in colorectal carcinoma patients. Cancer Immunol Immunother 1995;41(3):185-192.
43. Kitamura K, Stocken E, Garin CP, Chesa P, Welt S, Lloyd KO, et al.: Specificity analysis of blood group Lewis-y (Le(y)) antibodies generatedagainst synthetic and natural Le(y) determinants. Proc Natl Acad Sci USA 1994;91(26):12,957-12,961.
44. Kieber-Emmons T, Ward RE, Raychaudhuri S, Rein R, Kohler H: Rational design and application of idiotope vaccines. Int Rev Immunol 1986;1(1):1-26.
45. Diakun KR, Matta KL: Synthetic antigens as immunogens: Part III. Specificity analysis of an anti-anti-idiotypic antibody to a carbohydrate tumor-associated antigen. J Immunol 1989;142(6): 2037-2040.
46. Sugiyama T, Imai K, Ono A, et al.: Conformational structure of a monoclonal anti-idiotypic antibody to the monoclonal anti-adenocarcinoma-associated carbohydrate antibody YH206. J Immunol 1991;146(9):3097-3101.
47. Cheung NK, Cheung IY, Canete A, Yeh SJ, Kushner B, Bonilla MA, et al.: Antibody response to murine anti-GD2 monoclonal antibodies: correlation with patient survival. Cancer Res 1994;54(8):2228-2233.
48. Zanetti M, Lenert G, Springer GF: Idiotypes of pre-existing human anti-carcinoma anti-T and anti-Tn antibodies. Int Immunol 1993; 5(2):113-119.
49. Schmolling J, Reinsberg J, Wagner U, Krebs D: Antiidiotypic antibodies in ovarian cancer patients treated with the monoclonal antibody B72.3. Hybridoma 1995;14(2):183-186.
50. Fagerberg J, Frodin JE, Ragnhammar P, Steinitz M, Wigzell H, Mellstedt H: Induction of an immune network cascade in cancer patients treated with monoclonal antibodies (ab1). II. Is induction of anti-idiotype reactive T-cells (T3) of importance for tumor response to mAb therapy? Cancer Immunol Immunother 1994;38(3):149-159.
51. Fagerberg J, Hjelm AL, Ragnhammar P, Frodin JE, Wigzell H, Mellstedt H: Tumor regression in monoclonal antibody-treated patients correlates with the presence of anti-idiotype-reactive T lymphocytes. Cancer Res 1995;55(9):1824-1827.
52. Fagerberg J, Steinitz M, Wigzell H, Askelof P, Mellstedt H: Human anti-idiotypic antibodies induced a humoral and cellular immune response against a colorectal carcinoma-associated antigen in patients. Proc Natl Acad Sci USA 1995;92(11):4773-4777.
53. Ioannides CG, Freedman RS: T-cell responses to ovarian tumor vaccines: identification and significance for future immunotherapy [Review]. Int Rev Immunol 1991;7(4):349-364.
54. Tsuyuoka K, Yago K, Hirashima K, Ando S, Hanai N, Saito H, et al.: Characterization of a T-cell line specific toan anti-1d antibody related to the carbohydrate antigen, sialyl ssea-1, and the immunodominant T-cell antigenic site of the antibody. J Immunol 1996;157:661-669.
55. Apostolopoulos V, McKenzie IF: Cellular mucins: targets for immunotherapy [Review]. Crit Rev Immunol 1994;14(3,4):293-309.
56. Shattil SJ, Weisel JW, Kieber-Emmons T: Use of monoclonal antibodies to study the interaction between an integrin adhesion receptor. GPIIa-IIIb, and its physiological ligand, fibrinogen. Immun Meth 1993;1:53-63.
57. Prammer KV, Boyer J, Ugen K, Shattil SJ, Kieber-Emmons T: Bioactive Arg-Gly-Asp conformations in anti-integrin GPiib-iiia antibodies. Receptor 1994; 4:93-108.
58. Hansen JE, Clausen H, Hu SL, Nielsen JO, Olofsson S: An O-linked carbohydrate neutralization epitope of HIV-1 gp 120 is expressed by HIV-1 env gene recombinant vaccinia virus. Arch Virol 1992;126(1-4):11-20.
59. Hansen JE, Nielsen C, Arendrup M, Olofsson S, Mathiesen L, Nielsen J, et al.: Broadly neutralizing antibodies targeted to mucintype carbohydrate epitopes of human immunodeficiency virus. J Virol 1991;65(12):6461-6467.
60. Bernstein HB, Tucker SP, Hunter E, Schutzbach JS, Compans RW: Human immunodeficiency virus type I envelope glycoprotein is modified by O-linked oligosaccharides. J Virol 1994;68(1):463-468.
61. Y antigen in human immunodeficiency virus-infected human T-cell lines and in peripheral lymphocytes of patients with acquired immune deficiency syndrome (AIDS) and AIDS-related complex (ARC). J Exp Med 1988;167:323-331.
62. Lefebvre JC, Giordanengo V, Doglio A, Cagnon L, Breittmayer JP, Peyron JF, et al.: Altered sialylation of CD45 in HIV-1-infected T lymphocytes. Virology 1994; 199(2):265-274.
63. Arendrup M, Hansen JE, Clausen H, Nielsen C, Mathiesen LR, Nielsen JO: Antibody to histo-blood group A antigen neutralizes HIV produced by lymphocytes from blood group A donors but not from blood group B or O donors. AIDS 1991;5(4):441-444.
64. Gattegno L, Ramdani A, Jouault T, Saffar L, Gluckman JC: Lectin-carbohydrate interactions and infectivity of human immunodeficiency virus type 1 (HIV-1). AIDS Res Hum Retroviruses 1992;8(1):27-37.
65. Hansen JE, Sorensen AM, Arendrup M, Olofsson S, Nielson, JO, Janzek E, et al.: Enhancement of retroviral infection in vitro by anti-Le(y) IgG: reversal by humanization of monoclonal mouse antibody. Apmis 1993;101(9):711-718.
66. Furukawa K, Akagi T, Nagata Y, Yamada Y, Shimotohno K, Cheung N, et al.: GD2 ganglioside on human T-lymphotropic virus type 1-infected T-cells: possible activation of beta-1,4-N-acetylgalactosaminyl-transferase gene by p40tax. Proc Natl Acad Sci USA 1993;90(5): 1972-1976.